A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes
- Garcia-Manero, G.
- Khoury, H.J.
- Jabbour, E.
- Lancet, J.
- Winski, S.L.
- Cable, L.
- Rush, S.
- Maloney, L.
- Hogeland, G.
- Ptaszynski, M.
- Calvo, M.C.
- Bohannan, Z.
- List, A.
- Kantarjian, H.
- Komrokji, R.
ISSN: 1557-3265, 1078-0432
Year of publication: 2015
Volume: 21
Issue: 5
Pages: 985-994
Type: Article